1. The IPO represents 6.25 million shares of common stock, 25.6 percent of the company’s outstanding common stock following its conversion into a Delaware corporation in connection with the offering.
2. The IPO is expected to be $15 to $17 per share.
3. J.P. Morgan and BofA Merrill Lynch are the joint lead book-running managers for the offering. William Blair and Stifel are co-managers of the offering.
4. The offering’s underwriters will have a 30-day option to purchase up to an additional 937,500 shares of the company’s common stock.
5. EndoChoice applied to list its common stock under the symbol “GI” on the New York Stock exchange.
More articles on gastroenterology:
31 GI physicians making headlines – May 26, 2015
Mid-Bronx Endoscopy Center raises $835k
Synthetic Biologics presents 2 posters at Digestive Disease Week
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.